A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Sponsors Grifols
  • Most Recent Events

    • 19 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
    • 19 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
    • 14 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top